SPRAVATO® is one of the few treatments in psychiatry that people ask about by name, and the second question is always about money. This guide walks through what SPRAVATO® costs in practice, how insurance handles it, what the manufacturer's savings program does and does not cover, and how TRIP, our interventional psychiatry service line in Chesapeake, manages the process for you.
SPRAVATO® (esketamine) is a nasal spray approved by the FDA for adults with treatment-resistant depression and for depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or actions. Since January 2025 it is also approved as a stand-alone treatment for treatment-resistant depression, not only alongside an oral antidepressant. It is available only through an FDA safety program called a REMS, which means every dose is given in a certified clinic with at least two hours of monitoring afterward. It is never dispensed to take home.
So each treatment session has two parts with two costs: the medication itself, and the clinic visit where you receive it and are monitored. Insurance treats those two parts differently, which is the source of most of the confusion.
The standard course is twice a week for the first four weeks (the induction phase), then once a week for the next four weeks, then once a week or once every two weeks for as long as it keeps working. That is roughly twelve sessions in the first two months. Anyone quoting you a "cost of SPRAVATO®" without saying per session or per month is not giving you a useful number.
Most commercial plans, Medicare, and many Medicaid plans cover SPRAVATO® for adults who meet the FDA criteria, and nearly all of them require prior authorization first. TRIP is in-network with nearly every major plan, with TRICARE the notable exception. Insurers typically ask for documentation that you have major depressive disorder and that you have had an inadequate response to at least two antidepressants at adequate doses and durations; some still ask that you continue an oral antidepressant during treatment, though the monotherapy approval is slowly changing those policies. TRIP gathers the records, submits the request, and follows up with the insurer. Approvals often take one to two weeks. If a request is denied, we appeal with additional documentation, and denials are frequently overturned.
Your out-of-pocket cost then depends on your deductible, your copay or coinsurance, and whether the medication is billed under your medical benefit or your pharmacy benefit. Plans differ, and this is exactly why TRIP verifies your benefits and tells you what to expect before your first session rather than after.
The manufacturer's program can reduce the medication portion dramatically for people with commercial insurance. Eligible clients pay as little as $10 per treatment for the medication, up to an annual maximum benefit of $8,150 per calendar year. Three limits matter:
SPRAVATO® is generally covered by Medicare under the medical benefit, with the usual Part B cost-sharing, and by many Virginia Medicaid plans, typically with prior authorization. TRIP is in-network with nearly every major plan, so for most people the benefits check is a formality. Because the manufacturer's savings card cannot be used with government plans, the out-of-pocket picture is different from a commercial plan, and we walk through it with you individually. Do not assume it is unaffordable before we have checked.
The one exception is TRICARE. TRIP does not participate in the TRICARE network, and TRICARE does not use the manufacturer's savings card either. If you are a TRICARE beneficiary, call us before assuming SPRAVATO® is out of reach; there are sometimes referral or out-of-network paths worth exploring, and we will tell you plainly what is and is not possible.
Self-pay SPRAVATO® is expensive because the medication is expensive, and I will not pretend otherwise. If coverage is denied after appeal, we talk honestly about alternatives: optimizing oral medication, augmentation strategies, TMS through another provider, or in some cases racemic ketamine, which is off-label but less costly. My job is to find something that works within what you can actually sustain.
I already see a psychiatric provider. Can I get SPRAVATO® at TRIP and keep my prescriber? Yes. We coordinate with your existing provider, with your permission, and you come to TRIP only for treatment sessions.
Does the $300 SCP evaluation fee apply to SPRAVATO®? No. SPRAVATO® care runs through TRIP and is billed to your insurance. If you need a psychiatric evaluation and do not have a prescriber, South Chesapeake Psychiatry can provide it separately.
How do I start? Read about SPRAVATO® at TRIP, then contact the office. We begin with a benefits check and a review of your treatment history to confirm you meet the criteria.
If you are ready to be evaluated, or you simply want to ask whether we are the right fit, request an appointment or call the office at (757) 908-2124. South Chesapeake Psychiatry offers 60-minute self-pay psychiatric evaluations and ongoing medication management in Chesapeake and by secure video across Virginia. SPRAVATO® treatment is provided through TRIP, our insurance-supported interventional psychiatry service line.
Schedule an appointment today to get diagnosed, receive a prescription, and continue your journey towards mental peace.
